# Research Journal

<!-- Append only. One entry per agent invocation. Include phase transitions and editorial decisions. -->

### 2026-07-18 09:00 — librarian
**Phase:** Discovery
**Target:** phage_therapy_mdr_pseudomonas literature search
**Score:** N/A (scored by librarian-critic below)
**Verdict:** Found that (1) the "no phage therapy review since 2019" premise is false — at least six reviews exist since, most recently Liu et al. (2025, IJAA, IPD meta-analysis of 130 studies through May 2025) and Uyttebroek et al. (2022, Lancet ID); (2) essentially 0-1 qualifying comparative (dual-arm) studies exist for adjuvant phage therapy vs. antibiotic monotherapy specifically in MDR *Pseudomonas aeruginosa*, far below the 5-10 study feasibility threshold set in the discovery decision record. Both of the project's founding discovery decisions are challenged by this finding.
**Report:** quality_reports/literature/phage_therapy_mdr_pseudomonas/annotated_bibliography.md, frontier_map.md, positioning.md

### 2026-07-18 09:15 — librarian-critic
**Phase:** Discovery
**Target:** phage_therapy_mdr_pseudomonas literature search
**Score:** 84/100
**Verdict:** Headline feasibility finding (both the "no review since 2019" premise is false, and comparative MDR-Pseudomonas studies number 0-1 vs. the 5-10 threshold) holds up under stress-testing and is solid enough to escalate to the user now. One recommended pre-escalation step: independently confirm the core existence/DOI of Liu et al. (2025, IJAA) before finalizing the contribution statement, since it is unverified in references.bib but stated as settled fact in the prose driving the recommendation.
**Report:** quality_reports/literature/phage_therapy_mdr_pseudomonas/librarian_critic_review.md

### 2026-07-18 10:00 — librarian (Round 2, PRISMA-grade follow-up)
**Phase:** Discovery
**Target:** phage_therapy_mdr_pseudomonas literature search — user-requested rigorous follow-up before deciding on design pivot
**Score:** N/A (not re-scored by critic; user requested this as a verification step, not a new artifact to gate)
**Verdict:** Conclusion from Round 1 holds under stricter methodology. Ran 4 documented PubMed E-Utilities Boolean queries (54 raw hits, all screened) plus ClinicalTrials.gov API v2 structured search — found zero new qualifying comparative (dual-arm) MDR *P. aeruginosa* studies; one new not-yet-recruiting registered trial (NCT07698002, "DePHEAT-PJI") is the closest PICO match found but reports no data until 2027-2028. "Reviews since 2019" count revised upward to 8-9 (two more found: Terlizzi et al. 2026, Terzi et al. 2026). Liu et al. (2025, IJAA) fully verified via PubMed esummary (PMID 40633848), resolving the critic's top flagged concern. PROSPERO/WHO ICTRP only indirectly checked (session/JS-gated, no programmatic access). EMBASE, Web of Science, and Scopus remain unsearched — require the user's own institutional access; explicitly disclosed as an open gap, not resolved.
**Report:** quality_reports/literature/phage_therapy_mdr_pseudomonas/annotated_bibliography.md, positioning.md, frontier_map.md, references.bib (all updated in place with Round 2 section)

### 2026-07-18 14:00 — explorer
**Phase:** Discovery
**Target:** Data source feasibility assessment for the proportion meta-analysis (`/discover data`)
**Score:** 57/100 (Round 1, by explorer-critic)
**Verdict:** Assessed full-text access for 7 primary extraction-target studies and reusable structured datasets. Round 1 headline claims: ~86% of studies accessible (later found to be an arithmetic error), Liu et al. (2025) has no reusable dataset (later reversed).
**Report:** quality_reports/data-assessment/phage_therapy_mdr_pseudomonas/{data_sources.md, data_dictionary.md, access_instructions.md}

### 2026-07-18 14:10 — explorer-critic (Round 1)
**Phase:** Discovery
**Target:** Data source feasibility assessment
**Score:** 57/100 — below 80 commit gate
**Verdict:** Found a real arithmetic error (claimed 86%/4-of-7 open access; table only supported 71%/5-of-7) and an under-verified negative claim on Liu et al. (2025)'s dataset (403 on main URL is not proof of absence — Elsevier supplementary-CDN and PMC-linkout routes not attempted). Also flagged missing selection-effects/external-validity discussion for the two most accessible aggregate sources (Pirnay 2024, Israeli PTC) and a thin APT/BiomX rejection. Six fixes specified; one revision round required.
**Report:** quality_reports/data-assessment/phage_therapy_mdr_pseudomonas/explorer_critic_review.md

### 2026-07-18 14:20 — explorer (Round 2 fix)
**Phase:** Discovery
**Target:** Data source feasibility assessment
**Score:** N/A (fixes made per critic's 6 items; re-scored below)
**Verdict:** Corrected the arithmetic (5/7 = 71%, not 86%). Attempted the Elsevier supplementary-CDN route for Liu et al. (2025) — **succeeded**: `mmc2.pdf` is a real, reusable ~324-row case-level extraction dataset spanning ~130 studies, with fields overlapping this project's own extraction schema. Added selection-effects, external-validity, and corrections-check paragraphs for Pirnay/Israeli PTC; evidenced the APT/BiomX rejection with an SEC-filing check.
**Report:** quality_reports/data-assessment/phage_therapy_mdr_pseudomonas/{data_sources.md, data_dictionary.md, access_instructions.md} (revised in place)

### 2026-07-18 14:30 — explorer-critic (Round 2)
**Phase:** Discovery
**Target:** Data source feasibility assessment
**Score:** 89/100 — PASSES 80 commit gate
**Verdict:** All six Round 1 fixes verified as substantively addressed. Residual advisory (non-blocking): the Liu et al. mmc2.pdf claim remained an unverified single-agent PDF read pending independent confirmation.
**Report:** quality_reports/data-assessment/phage_therapy_mdr_pseudomonas/explorer_critic_review.md (Round 2 section appended)

### 2026-07-18 14:40 — Orchestrator (independent verification)
**Phase:** Discovery
**Target:** Liu et al. (2025) mmc2.pdf dataset — independent confirmation requested by explorer-critic
**Score:** N/A (verification action, not a scored artifact)
**Verdict:** Independently fetched and read `mmc2.pdf` directly. Confirmed: genuine ~324-row case-level dataset with the exact field names reported, plus additional risk-of-bias assessments (RoB2 for 9 RCTs, ROBINS-I for 2 comparative cohorts, NHLBI/JBI checklists for ~90 studies/cases) not fully surfaced in the explorer's report. **New finding:** the RCT table lists Krakhotkin et al. (2025, Curr Urol) — a phage-alone-or-plus-antibiotics vs. antibiotics-only comparative study not previously found by this project's own librarian searches — plus four other uncatalogued trials (Leitner 2021, Karn 2024, Rhoads 2009, Stanley 2024) requiring a Pseudomonas/MDR relevance check.
**Report:** quality_reports/data-assessment/phage_therapy_mdr_pseudomonas/explorer_critic_review.md (Independent Orchestrator Verification section appended)

### 2026-07-19 — PDF corpus screening (ad hoc, local 201-document PubMed/Elicit export)
**Phase:** Discovery
**Target:** Title/abstract PRISMA screening of 201 PDFs in `C:\Users\Equipo\Desktop\PUBMED ELICIT` against the project's PICO eligibility criteria
**Score:** N/A (screening action, not a scored critic artifact)
**Verdict:** Applied the user-supplied rigorous 4-criteria methodology (P/I/S/Antigüedad, replicated from a prior reference screening of 76 documents, `Cribado_Sistematico_COMPLETO_76_3.xlsx`) — INCLUIDO only if all 4 = Cumple, using the fixed "desde 2019" cutoff as a formal gating criterion. Result: **12 INCLUIDO / 189 EXCLUIDO** (189 = 54 preclinical-in-vitro, 46 preclinical-animal, 42 review-non-primary, 18 not-phage-therapy, 15 mechanistic-non-phage, 11 wrong-pathogen, 3 other). Of the 12 INCLUIDO, 3 are exact duplicates of papers already screened and INCLUDED in the 76-document reference (Aslam et al. 2019, Teney et al. 2024, Van Nieuwenhuyse et al. 2022) — 9 are genuinely new candidates for data extraction: Tkhilaishvili et al. 2020 (PJI), Blasco et al. 2023 (vascular graft, phage failure — year inferred, flagged for verification), Ngauy et al. 2026 (hypermutator osteomyelitis), Dan et al. 2023 (host immune response — flagged as possible same patient as one of the Aslam 2019 cases, needs dedup check before extraction), Ferry et al. 2022 (spinal PDR abscess), Liu et al. 2025 (perinephric abscess, 2 KTR cases), Racenis et al. 2023 (LVAD driveline) and 2022 (femur osteomyelitis). Cross-checked against `references.bib` (34 entries) — no duplicates found there. One first-pass DUDA item (Rose et al. 2014, burn wound, mixed S. aureus/P. aeruginosa cohort) resolved to EXCLUIDO on Antigüedad grounds alone (2014 < 2019), independent of the pathogen-mix ambiguity. Flagged one exclude-but-noteworthy lead: "Phage Therapy for Cardiac Implantable Electronic Devices and Vascular Grafts — A Targeted Literature Review" (2024) aggregates 17 primary studies/34 patients — worth backward-citation-chasing for more candidates.
**Report:** `quality_reports/literature/phage_therapy_mdr_pseudomonas/Cribado_Sistematico_201_PubMed_Elicit.xlsx` (2 sheets: `Cribado_Completo_201`, `Resumen`)

### 2026-07-19 — librarian-critic (Round 3, five new study leads)
**Phase:** Discovery
**Target:** Round 3 screening of Krakhotkin/Leitner/Karn/Rhoads/Stanley leads
**Score:** 78/100 — below 80 commit gate
**Verdict:** Krakhotkin (2025) and Leitner (2021) substantively solid additions, but flagged: an unreconciled cross-round citation-chase gap (PMID 30051571 vs. Leitner's PMID 32949500), Krakhotkin verified only via secondary sources (not this project's own established direct-PubMed gold standard), a proximity-score/narrative contradiction (Krakhotkin scored below "incremental" Stanley despite being called most consequential), and inconsistent Rhoads/Karn eligibility treatment. One targeted fix round recommended, not escalation.
**Report:** quality_reports/literature/phage_therapy_mdr_pseudomonas/librarian_critic_review.md (Round 3 section)

### 2026-07-19 — librarian (Round 3 fix pass)
**Phase:** Discovery
**Target:** Close the 4 items from librarian-critic's Round 3 review
**Score:** N/A (fixes made; re-scored below)
**Verdict:** Ran live PubMed E-Utilities calls (not just prose edits) for all items. Confirmed PMID 30051571 is McCallin et al. (2018, Environmental Microbiology) — a genuinely separate Phase I safety study, not an earlier Leitner report; added the missing `McCallin2018_envmicrobiol` bib entry. Directly verified Krakhotkin (PMID 40314011) via esummary+efetch, confirming the 4-arm design and n=178. Re-scored Krakhotkin's proximity to tie Leitner/Stanley. Gave Rhoads/Karn an explicit, non-overlapping justification (antibiotic-comparator structure, not shared pathogen-specificity uncertainty). Unplanned finding: caught and corrected two fabricated author names and two omitted real co-authors in Leitner's previously-recorded byline.
**Report:** quality_reports/literature/phage_therapy_mdr_pseudomonas/{annotated_bibliography.md, references.bib}

### 2026-07-19 — librarian-critic (Round 3 re-review)
**Phase:** Discovery
**Target:** Verify the Round 3 fix pass
**Score:** 93/100 — PASSES 80 commit gate and 90 PR gate
**Verdict:** All four Round 3 deductions genuinely closed with specific, falsifiable, cross-checked evidence, not re-assertion. The Leitner fabrication correction is transparently disclosed with its verification method — a strength, not just a fix. Minor residual advisory items: dual proximity-scale convention across rounds unreconciled; no verbatim raw API transcripts embedded.
**Report:** quality_reports/literature/phage_therapy_mdr_pseudomonas/librarian_critic_review.md (Round 3 Re-Review section appended)

### 2026-07-19 — strategist
**Phase:** Strategy
**Target:** Meta-analysis-of-proportions strategy memo
**Score:** N/A (scored by strategist-critic below)
**Verdict:** Produced Pre-Strategy Report + full strategy memo: GLMM (binomial-normal, logit link) as primary pooling model (deviating from domain-profile.md's stated double-arcsine, justified by Schwarzer et al. 2019's back-transformation-failure risk under this corpus's extreme sample-size heterogeneity — flagged for user approval to update domain-profile.md); 4-step MDR/XDR classification ladder; a 3-tier Liu et al. (2025) dataset reuse policy (scoping + cross-validation as default, direct adoption requires explicit user sign-off); RoB approach; sensitivity/robustness plan; 6 falsification tests; 8 referee-objection responses; PROSPERO timing argument.
**Report:** quality_reports/strategy_memo_phage_therapy_mdr_pseudomonas.md, quality_reports/strategy/phage_therapy_mdr_pseudomonas/{pseudo_code.md, robustness_plan.md, falsification_tests.md}

### 2026-07-19 — strategist-critic (Round 1)
**Phase:** Strategy
**Target:** Strategy memo
**Score:** 84/100 — above 80 commit gate, no CRITICAL issues
**Verdict:** Core design (estimand, stratification cleanly separated from paired comparison, GLMM justification) holds. 4 MAJOR items flagged before locking into PROSPERO: no GLMM convergence-failure contingency; Liu et al. Tier-2 audit has a copy-and-relabel loophole; PROSPERO §8 disclosure doesn't name the GLMM choice's own scoping-phase data-dependency; referee objection #7 doesn't address testing multiplicity. Recommended fixing before protocol registration, not blocking otherwise.
**Report:** quality_reports/strategy_memo_phage_therapy_mdr_pseudomonas_review.md

### 2026-07-19 — strategist (fix pass)
**Phase:** Strategy
**Target:** Close the 4 MAJOR + 1 MINOR items from strategist-critic's review
**Score:** N/A (fixes made; re-scored below)
**Verdict:** Added GLMM convergence-failure tryCatch/classification with cell-level logit-DL fallback and mandatory footnoting; added a documented primary-source-citation requirement for a random subsample of Liu-overlapping "independently-extracted" rows; explicitly named the GLMM-choice/scoping-data-dependency in the PROSPERO §8 disclosure; added a multiplicity-of-testing rationale (Cochrane Handbook hypothesis-generating convention) to referee objection #7; noted the XDR-shrinkage trade-off in Limitations.
**Report:** quality_reports/strategy_memo_phage_therapy_mdr_pseudomonas.md, quality_reports/strategy/phage_therapy_mdr_pseudomonas/pseudo_code.md (revised in place)

### 2026-07-19 — strategist-critic (Re-Review)
**Phase:** Strategy
**Target:** Strategy memo fix pass
**Score:** 95/100 — PASS, commit gate cleared with margin
**Verdict:** All 4 MAJOR + 1 MINOR items genuinely resolved, not cosmetically patched. No new issues introduced. Memo ready to inform the coder/data-engineer's extraction spreadsheet, and (pending user sign-off) ready to support PROSPERO registration.
**Report:** quality_reports/strategy_memo_phage_therapy_mdr_pseudomonas_review.md (Re-Review section appended); quality_reports/decisions/strategy_phage_therapy_mdr_pseudomonas.md (decision record)

### 2026-07-20 — data-engineer + orchestrator (extraction dataset construction)
**Phase:** Execution
**Target:** Build the extraction dataset per the approved strategy memo's schema
**Score:** N/A (data construction, not a scored critic artifact — coder-critic will review the eventual analysis code)
**Verdict:** A data-engineer dispatch (interrupted twice by API errors, work preserved across restarts) built `data/raw/phage_therapy_extraction_raw.csv` and `scripts/R/clean_phage_extraction.R`. The orchestrator then independently extracted/verified the remaining highest-priority studies via direct WebFetch/WebSearch of primary sources (PMC, journal sites, ClinicalTrials.gov): Pirnay 2024 (11/49-patient subset from Table 2), Onallah/Green 2023 PASA16 (resolved author-name error: Onallah, not Green), Weiner 2025/BX004-A (confirmed 7 phage/2 placebo arm split), Jault 2019/PhagoBurn, Aslam 2019 (2 new Pseudomonas patients), Armata AP-PA02. Two critical corrections: **Krakhotkin 2025 excluded** (confirmed via full text to contain zero P. aeruginosa cases, contradicting its prior "most consequential finding" framing) and **Dan2023 excluded as a confirmed duplicate** of Aslam2019 Patient 1. A targeted Round 4 literature search (dispatched to librarian) confirmed **no usable antibiotic-monotherapy comparator exists** for Pseudomonas in this literature — the monotherapy stratum is reported as insufficient evidence per the strategy memo's pre-specified rule. R environment required installing packages (dplyr, readr, here, meta, metafor, clubSandwich, ggplot2) to a user library since the system library was not writable; cleaning script now runs successfully.
**Report:** `data/raw/phage_therapy_extraction_raw.csv`, `data/cleaned/phage_therapy_extraction_dataset.csv`, `data/cleaned/phage_therapy_extraction_codebook.md`, `quality_reports/data_extraction_summary_phage_therapy_mdr_pseudomonas.md`, `quality_reports/decisions/strategy_phage_therapy_mdr_pseudomonas.md` (monotherapy-stratum update)

### 2026-07-20/21 — coder (GLMM meta-analysis pipeline)
**Phase:** Execution
**Target:** Implement the meta-analysis of proportions per the approved strategy memo
**Score:** N/A (scored by coder-critic below)
**Verdict:** Built a 9-script R pipeline (`00_master.R` through `08_tables.R` + `functions/`) implementing GLMM-primary/logit-DL-fallback pooling with the full convergence contingency, 4 outcome families, MDR/XDR × route × modality stratification, and the monotherapy-stratum skip. Ran successfully end-to-end. Headline results: clinical success 86.1% [68.2%, 94.7%] (k=10, N=36), eradication 71.4% [46.0%, 88.0%] (k=9, N=21). Flagged its own key caveat: the safety/AE GLMM estimate (1.0%) is numerically unstable (near-complete separation, 11/12 arms report zero AEs) — sensitivity models (~31%) are more credible and were recommended over the raw GLMM figure.
**Report:** `scripts/R/00_master.R` (+ pipeline scripts), `quality_reports/results_summary_phage_therapy_mdr_pseudomonas.md`, `paper/tables/phage_therapy_mdr_pseudomonas/`, `paper/figures/phage_therapy_mdr_pseudomonas/`

### 2026-07-21 — coder-critic (Round 1)
**Phase:** Execution
**Target:** Meta-analysis pipeline code review (12-category checklist, strict severity)
**Score:** 64/100 — below 80 commit gate
**Verdict:** Found 1 CRITICAL bug (unescaped `%` in generated LaTeX breaks table compilation) and 3 MAJOR gaps (outcome×stratum scope silently narrowed to 2/4 outcomes; prediction interval missing from the numeric table; 6/13 pre-specified robustness checks + Falsification Test 5 missing without disclosure), plus 4 MINOR items. Independently re-derived every headline number from the raw CSV — all matched exactly; confirmed the coder's self-reported GLMM safety-instability caveat is mechanistically accurate, not fabricated.
**Report:** `quality_reports/meta_analysis_phage_therapy_code_review.md`

### 2026-07-21 — coder (fix pass, Round 1 -- interrupted by API error, completed by orchestrator)
**Phase:** Execution
**Target:** Close the 8 items from coder-critic's Round 1 review
**Score:** N/A (fixes made; re-scored below)
**Verdict:** Fixed the CRITICAL escaping bug, extended the outcome×stratum loop to all 4 outcomes, added the prediction-interval column, implemented all 6 missing robustness checks (MDR/XDR classification sensitivity, study-design sensitivity, geographic-concentration exclusion, route-collapsing alternative, Liu-reuse-tier transparency, threshold-relaxation appendix) and Falsification Test 5 (LOS, correctly NOT_APPLICABLE given only 1/15 arms report `los_days`), plus all 4 MINOR items (`.libPaths()` fix, serif forest plots, vapply refactor, by-script subfolder organization). Full pipeline re-run confirmed successful end-to-end.
**Report:** `scripts/R/04_estimation.R`, `05_robustness.R`, `06_falsification.R`, `07_figures.R`, `08_tables.R`, `clean_phage_extraction.R` (revised in place)

### 2026-07-21 — coder-critic (Re-Review, Round 2)
**Phase:** Execution
**Target:** Verify the Round 1 fix pass
**Score:** 97/100 — PASS, clears both 80 commit gate and 90 PR gate
**Verdict:** All 4 previously-blocking issues (1 CRITICAL, 3 MAJOR) genuinely resolved, independently verified against actual generated artifacts and raw data (not just code). Two trivial new findings (harmless dead code, one stale comment), both non-blocking. `results_summary.md` still correctly discloses the GLMM safety-instability caveat. Safe to advance to writer/paper-drafting phase.
**Report:** `quality_reports/meta_analysis_phage_therapy_code_review.md` (Re-Review section appended)

### 2026-07-21 — writer
**Phase:** Execution
**Target:** Draft `paper/sections/intro.tex` (IMRaD Introduction, per domain-profile.md's 2026-07-21 Paper Structure decision — not the econ working-paper structure)
**Score:** N/A (pending writer-critic review)
**Verdict:** Drafted a 5-paragraph, 493-word Introduction (burden/motivation → state of prior syntheses → the design-gap/monotherapy-failure pivot → PICO objectives → honest forward-reference to the evidence-gap finding). Framing follows the final research-spec/decision-record contribution (evidence-gap synthesis, not "first update since 2019" or an efficacy claim) — explicitly states the pooled 86.1% clinical-success proportion is a salvage-population artifact, not a treatment effect, and that the monotherapy comparator and all resistance/route strata could not be pooled. Added 6 new bib entries to `Bibliography_base.bib`: 3 copied verbatim from the librarian's verified `references.bib` (ElHaddad2019_eskape, Uyttebroek2022_lancetid, Liu2025_ijaa) and 3 seminal methodological citations (Magiorakos2012_mdrxdr, Tacconelli2018_who, Page2021_prisma) independently verified by the writer via direct PubMed E-Utilities esummary calls, since these were not part of the librarian's discovery bibliography. **VOICE flag:** `.claude/references/personal-style-guide.md` is still an unfilled template — drafted in generic concise clinical/IMRaD voice per domain-profile.md; recommend `/write style-guide` before further sections if a calibrated personal voice is wanted.
**Report:** `paper/sections/intro.tex`; `quality_reports/claim_source_map_phage_therapy_mdr_pseudomonas.md`

### 2026-07-21 — writer-critic
**Phase:** Execution
**Target:** Review `paper/sections/intro.tex`
**Score:** 95/100 — PASS, clears both 80 commit gate and 90 PR gate
**Verdict:** No CRITICAL issues. Every numerical/factual claim independently checked against results_summary.md and the decision records — all matched exactly. The "no efficacy overclaiming" check (the most important check for this paper type) passes explicitly: the 86.1% pooled proportion is correctly framed as a salvage-population artifact, not a treatment-effect finding. All 6 citations verified valid. Only finding: inconsistent em-dash spacing (4 instances) — fixed by the orchestrator post-review.
**Report:** `quality_reports/intro_writer_critic_review.md`

### 2026-07-21 — writer (Methods section)
**Phase:** Execution
**Target:** Draft `paper/sections/methods.tex` (IMRaD Methods: Protocol/Registration, Eligibility, Search Strategy, Study Selection, Data Extraction, Risk-of-Bias, Outcomes/Statistical Analysis)
**Score:** N/A (pending writer-critic review)
**Verdict:** Drafted a fully-traced Methods section documenting the actual process, including honest disclosures the writer independently verified against raw data before writing: PROSPERO was never registered; risk-of-bias ratings are complete for only 10 of 16 arms; the Liu et al. (2025) Tier-2 cross-validation was planned but never executed (every row is `independently-extracted`); EMBASE/Web of Science/Scopus were not searched by the review team. Added 17 new verified bibliography entries.
**Report:** `paper/sections/methods.tex`; `quality_reports/claim_source_map_phage_therapy_mdr_pseudomonas.md` (updated)

### 2026-07-21 — writer-critic (Round 1)
**Phase:** Execution
**Target:** Review `paper/sections/methods.tex`
**Score:** 64/100 — below 80 commit gate
**Verdict:** Found 1 CRITICAL factual error (Risk-of-Bias section undercounted RCTs among incomplete arms as "three" when the data shows four) plus 6 minor/major issues (untraced "100-patient" figure, missing Magiorakos citations, duplicated Krakhotkin citation, an intro/methods review-count mismatch, a provenance-tag ambiguity, and a repetitive "X, not Y" writing tic). All honesty-critical claims (PROSPERO non-registration, RoB 10/6 split, Tier-2 non-execution, EMBASE/WoS/Scopus gap) independently verified as accurate.
**Report:** `quality_reports/methods_writer_critic_review.md`

### 2026-07-21 — writer (fix pass)
**Phase:** Execution
**Target:** Close the 7 items from writer-critic's review
**Score:** N/A (fixes made; re-scored below)
**Verdict:** Corrected the RCT count to four; traced the "100-patient" figure; added missing Magiorakos citations; fixed the duplicated Krakhotkin citation; reconciled the review-count mismatch to "eight" (verified the 9th post-2019 synthesis is preclinical/animal-only, not human); clarified the provenance-tag scope; trimmed the repetitive writing construction while preserving every substantive disclosure.
**Report:** `paper/sections/methods.tex` (revised in place)

### 2026-07-21 — writer-critic (Re-Review)
**Phase:** Execution
**Target:** Verify the Methods fix pass
**Score:** 97/100 — PASS, clears both 80 commit gate and 90 PR gate
**Verdict:** All 7 items independently re-verified as genuinely fixed against source data (including re-deriving the RCT count directly from the extraction CSV). No new errors introduced. Two trivial residual items (deferred `\cref{}` conversion, slightly discursive register) are non-blocking.
**Report:** `quality_reports/methods_writer_critic_review.md` (Re-Review section appended)

### 2026-07-21 — writer (Results section)
**Phase:** Execution
**Target:** Draft `paper/sections/results.tex` (Study Selection, Study Characteristics, Risk of Bias, Synthesis of Pooled Outcomes, Sensitivity/Robustness, Falsification checks)
**Score:** N/A (pending writer-critic review)
**Verdict:** Drafted a fully-traced Results section reporting all 5 pooled cells, all 32 not-pooled cells (the review's central finding), the GLMM safety-instability caveat, and the significant Egger's test results honestly. Flagged two BLOCKED items: 6 of 7 case-report studies extracted directly (bypassing the librarian) had no bibliography entry, and a pre-existing citation error (Green vs. Onallah) needed correcting.
**Report:** `paper/sections/results.tex`

### 2026-07-21 — writer-critic (Round 1)
**Phase:** Execution
**Target:** Review `paper/sections/results.tex`
**Score:** 57/100 — FAILS 80 commit gate, 2 CRITICAL issues
**Verdict:** (1) Bibliography gap confirmed real and only 25% closed — 6 of 8 newly-added citations were never actually used in the prose. (2) Internal multi-agent pipeline jargon ("the domain-referee concern") leaked into manuscript prose — would be unintelligible to a real journal reader. All other content (86.1% framing, GLMM instability, Egger's significance, not-pooled strata) verified clean.
**Report:** `quality_reports/results_writer_critic_review.md`

### 2026-07-21 — Orchestrator (fix pass)
**Phase:** Execution
**Target:** Close the 2 CRITICAL + 2 MINOR items from writer-critic's review
**Score:** N/A (fixes made; re-scored below)
**Verdict:** Independently verified and added 7 new citation entries to `Bibliography_base.bib` (Tkhilaishvili2020, Blasco2023, Ferry2022, Ngauy2026, Racenis2022, Racenis2023, Liu2025_perinephric perinephric-abscess series) plus corrected the Onallah/Green author-attribution error (in both Bibliography_base.bib and the discovery-phase literature bib). Cited all 6 previously-uncited studies in results.tex's Study Characteristics subsection. Removed leaked pipeline jargon. Moved all 4 figure notes inside `\caption{}` per INV-2. Fixed a confusing divergence-count sentence.
**Report:** `paper/sections/results.tex`, `Bibliography_base.bib`, `quality_reports/literature/phage_therapy_mdr_pseudomonas/references.bib` (revised in place)

### 2026-07-21 — writer-critic (Re-Review)
**Phase:** Execution
**Target:** Verify the Results fix pass
**Score:** 97/100 — PASS, clears both 80 commit gate and 90 PR gate
**Verdict:** Both CRITICAL issues and both MINOR issues genuinely resolved, independently re-verified against Bibliography_base.bib and the file itself. No regression in previously-clean numbers (86.1% CI, GLMM safety instability, Egger's p-values).
**Report:** `quality_reports/results_writer_critic_review.md` (Re-Review section appended)

### 2026-07-21 — writer (Discussion section)
**Phase:** Execution
**Target:** Draft `paper/sections/discussion.tex` (Summary of Main Findings, Comparison with Prior Syntheses, Safety Findings/Small-Study Effects, Limitations, Implications, Conclusion)
**Score:** N/A (pending writer-critic review)
**Verdict:** Drafted the final section, owning the evidence-gap finding as the paper's actual contribution rather than hedging around it. Ranked 4 limitations by actual inferential impact with stated directions of bias, argued the corpus's own small-study effects warrant skepticism toward the broader field's high-success narrative (not just this review's numbers), and closed with a narrow, defensible conclusion naming the single most useful next step (a comparative study with a genuine monotherapy arm).
**Report:** `paper/sections/discussion.tex`

### 2026-07-21 — writer-critic (3 rounds)
**Phase:** Execution
**Target:** Review `paper/sections/discussion.tex`
**Score:** 74/100 → 89/100 → 96/100 (final PASS, clears both 80 commit and 90 PR gates)
**Verdict:** Round 1 found 1 CRITICAL issue (an unsupported, undirectional claim about grey-literature bias direction) plus an RCT-count inconsistency with results.tex and an overclaimed numerical agreement with prior syntheses. Round 2 fix reintroduced the grey-literature claim with backwards polarity (caught by the critic cross-referencing the section's own small-study-effect finding). Round 3 fixed the polarity correctly. Also verified: the "one unrated trial drives both the RoB gap and the safety instability" inference holds up against the raw extraction data.
**Report:** `quality_reports/discussion_writer_critic_review.md`

**All four paper sections now complete and approved:** Introduction (95/100), Methods (97/100), Results (97/100), Discussion (96/100).

### 2026-07-22 — main.tex assembly + compilation debugging
**Phase:** Execution (verification)
**Target:** `paper/main.tex` (assembled from all four approved sections) and its LaTeX compilation
**Score:** N/A (infrastructure/verification task, not a scored agent artifact)
**Verdict:** After installing MiKTeX Portable and running `latexmk main.tex`, hit a cascading compile failure (Missing \endgroup, itemize/end{document} mismatch, Package graphics Division by 0). Root cause traced to `Bibliography_base.bib`: every `note = {% ...}` field's leading `%` was a literal unescaped LaTeX comment character, which corrupted biber's generated `main.bbl` mid-`\field{}` argument (ate the closing brace and everything after), and that single corruption cascaded into all the downstream itemize/group errors reported in unrelated sections. Fixed 36 unescaped `%`, 41 unescaped `_` (mostly in note-field file-path text), one more unescaped `%` in a percentage figure, and removed two `\resizebox{\textwidth}{!}{...}` wrappers around table `\input{}` calls in results.tex that were separately breaking `threeparttable`. Also added `fontspec` + `\setmainfont{Latin Modern Roman}` to render Savović's `ć`, absent from the legacy 8-bit T1/lmodern font XeLaTeX was using. Final result: exit code 0, zero fatal errors, all citations/references resolved, `paper/main.pdf` produced (45 pages).
**Report:** `SESSION_REPORT.md` (2026-07-22 11:06 entry has full diagnostic detail)

### 2026-07-22 — PRISMA 2020-adapted flow diagram built (Figure 1)
**Phase:** Execution (Results section, addressing a previously-disclosed limitation)
**Target:** `paper/figures/phage_therapy_mdr_pseudomonas/prisma_flow_diagram.tex` (new, hand-built TikZ), `paper/sections/results.tex` (Study Selection subsection updated)
**Score:** N/A (figure-drawing from already-verified counts, not a new data analysis; not a scored critic artifact)
**Verdict:** Built a PRISMA 2020-adapted flow diagram reconciling every identification/screening/eligibility/inclusion count already stated in the approved Methods/Results text, cross-referenced against the cleaned dataset's 14 unique study_id values and the librarian's annotated bibliography to correctly attribute each included study to its actual identification channel (4 documented search rounds; citation-chasing; the 201-doc PDF corpus; and a previously-unquantified original discovery-phase scoping channel that contributed 6 of the 14 included studies -- newly disclosed in results.tex). While building this, found and fixed two real, previously-undetected bugs that had survived 3 rounds of writer-critic review: (1) `Pirnay2024_natmicrobiol` and `Jault2019_phagoburn` had no `author` field in Bibliography_base.bib, causing every citation to them anywhere in the approved paper to silently render as the full article title instead of "Author et al. (Year)" -- invisible from reading .tex source, only caught by visually inspecting the compiled PDF; (2) `Weiner2025_natcomms` (one of the 15 pooling-eligible study-arms) had no bibliography entry at all, the same "extracted directly, bypassed librarian" gap class caught once before during the Results review. All three fixed with PubMed-verified author lists. Full diagram, all citations, and the paper compile cleanly (exit 0, zero fatal errors, zero undefined references in the final pass).
**Report:** `quality_reports/claim_source_map_phage_therapy_mdr_pseudomonas.md` (new "PRISMA Flow Diagram" section)

### 2026-07-22 — Table 1 (Study Characteristics) built
**Phase:** Execution (Results section, addressing a previously-disclosed limitation)
**Target:** `scripts/R/09_table1_characteristics.R` (new), `paper/tables/phage_therapy_mdr_pseudomonas/table1_study_characteristics.tex` (new, R-generated), `paper/sections/results.tex` (Study Characteristics subsection updated)
**Score:** N/A (descriptive table generation from the already-cleaned dataset, not a new critic-scored artifact)
**Verdict:** Built the study-characteristics table flagged as a deferred addition in the Results section's own prose ("a formal Table 1 is a reasonable addition before submission"). One row per study-arm (16 rows, all 14 studies including the pooling-excluded Leitner arm): Study, Country/region, Design, n, Resistance, Route, Modality, Pooling status. All counts cross-checked against the already-approved Section 3.2 prose (resistance/route/modality tallies) -- exact match. First version overflowed the page width (~168pt, confirmed via Overfull hbox + visual PDF check showing columns cut off); fixed by abbreviating cell content and switching to \scriptsize + tightened \tabcolsep, not \resizebox (which is now known to break with threeparttable, per the earlier main.tex compilation fix this session). Added as a new step in the 00_master.R pipeline sequence (09_table1_characteristics.R). Paper compiles cleanly: exit 0, zero fatal errors, zero undefined references in the final pass.
**Report:** `quality_reports/claim_source_map_phage_therapy_mdr_pseudomonas.md` (new "Table 1" section)

### 2026-07-22 — Pirnay 2024 full re-extraction (32 MDR/XDR/PDR patients) + full-paper renumbering
**Phase:** Execution (completing pending extractions, then re-propagating through Results/Discussion/Abstract)
**Target:** `data/raw/phage_therapy_extraction_raw.csv`, `scripts/R/functions/pool_stratum.R`, `scripts/R/08_tables.R`, `paper/sections/{intro,methods,results,discussion}.tex`, `paper/main.tex` (abstract)
**Score:** N/A (data completion + cascading rewrite, not a single scored artifact; recommend a fresh writer-critic pass on all four sections given the scale of the rewrite)
**Verdict:** Found Pirnay et al. (2024)'s full 100-patient supplementary data as an open-access PMC mirror (PMC11153159), previously missed. Re-extracted all 49 P. aeruginosa-targeted patients (matching the paper's own "49/100" figure exactly); found 17 are UDR (ineligible per this review's own MDR/XDR/PDR criterion, a genuine correction affecting 2 patients already in the old 11-patient subset); the remaining 32 replace the old aggregate row as 3 resistance-stratified arms (7 XDR, 23 MDR, 2 PDR). Headline consequence: MDR is now POOLED across all 4 outcomes for the first time (previously the review's core stratification aim was entirely blocked); Egger's test reversed from significant to non-significant for both eligible outcomes; total N rose 66→87. Re-running the pipeline surfaced and required fixing a real code bug (unprotected sensitivity-model calls in `pool_stratum.R` crashing on a near-complete-separation cell) and a real table-rendering bug (two 8-column results tables silently overflowing the page width, caught only by page-by-page visual verification, not by any compile-only check). Rewrote `intro.tex`, `methods.tex`, `results.tex`, and `discussion.tex` substantively (not just number substitution) since the underlying narrative — evidence-gap framing, small-study-effects framing, Pirnay-selection-bias framing — changed along with the numbers. Caught and fixed one self-introduced inconsistency (claimed sensitivity models "cluster close" to GLMM for safety when the actual divergence remained >5pp and one model failed to converge) and one self-introduced factual error (conflated "extraction complete" with "risk-of-bias complete" for Pirnay's new rows, which are outcome-complete but not yet RoB-rated). Final compile: exit 0, zero fatal errors, zero undefined references, all four meta-analysis tables and Table 1 visually re-verified via `pdftoppm` render.
**Report:** `quality_reports/claim_source_map_phage_therapy_mdr_pseudomonas.md` ("Pirnay 2024 Full Re-Extraction" section), `quality_reports/results_summary_phage_therapy_mdr_pseudomonas.md` (fully rewritten)

### 2026-07-22 — Jault2019/PhagoBurn + ArmataAP_PA02 completion via new MCP tools (2 of remaining 5 pending extractions)
**Phase:** Execution (completing pending extractions, second wave)
**Target:** `data/raw/phage_therapy_extraction_raw.csv`, `scripts/R/08_tables.R` (label_stratum abbreviation fix), `paper/sections/{results,discussion}.tex`, `paper/main.tex` (abstract)
**Score:** N/A (data completion + surgical number updates, not a scored artifact)
**Verdict:** Newly available PubMed and ClinicalTrials.gov API v2 MCP tools resolved 2 of the 5 remaining EXTRACTION_INCOMPLETE arms with real, verifiable structured data: Jault2019/PhagoBurn (adverse_event_n=3, mortality_n=1, from a full structured PubMed abstract) and ArmataAP_PA02/SWARM-Pa (mortality_n=0, confirmed adverse_event_n=5/10, from a direct ClinicalTrials.gov API v2 query against the trial's actual results module). Also resolved Weiner2025's outstanding Author-Correction-verification flag (confirmed no effect on results) and obtained richer confirmatory abstracts for Onallah2023 and Leitner2021, though both remain genuinely incomplete (no PMC full text exists for either, confirmed via citation-linkage lookup) — Onallah's exact AE count and Leitner's Pseudomonas-subgroup breakdown are not resolvable from anything short of full-text access this review team doesn't have. Pipeline re-run: COMPLETE arms 13→15, pooled cells 12→14 (new: safety and mortality in the not-classifiable resistance stratum), overall safety 14.2%→18.2%, overall mortality newly POOLED at 10.8% (was NOT_POOLED), Egger's gained a third eligible outcome (mortality, p=0.074, not significant). Found and fixed a second table-width overflow (the 2 new rows pushed `meta_pooled_estimates.tex` back over the page width even at scriptsize) by abbreviating "not-classifiable" to "NC" consistently with Table 1. Final compile: exit 0, zero fatal errors, zero undefined references, both affected tables re-verified via `pdftoppm` render within page margins.
**Report:** `quality_reports/claim_source_map_phage_therapy_mdr_pseudomonas.md` ("Jault2019/PhagoBurn + ArmataAP_PA02 Completion" section), `quality_reports/results_summary_phage_therapy_mdr_pseudomonas.md` ("Second Update" section)

### 2026-07-22 — Risk-of-bias completion (8 arms) + writer-critic pass (fresh, 62/100) + fix round
**Phase:** Execution → Peer-Review-adjacent (a genuine fresh writer-critic pass, not a delta-check, given the scale of same-day rewrites)
**Target:** `quality_reports/risk_of_bias_assessment_phage_therapy_mdr_pseudomonas.md` (new), `data/raw/phage_therapy_extraction_raw.csv` (`rob_source` for 8 arms), `paper/sections/{methods,results,discussion}.tex`, `paper/main.tex`
**Score:** 62/100 (writer-critic, fresh full review) → fix round applied → re-review dispatched (see next entry for outcome)
**Verdict:** Completed risk-of-bias ratings for all 8 previously-unrated arms: RoB2 for the 4 RCTs (PhagoBurn rated **High risk** — unmasked clinicians, stopped early for futility; Leitner2021 and Weiner2025/BX004-A rated Some concerns; ArmataAP_PA02/SWARM-Pa rated Low risk, verified directly against ClinicalTrials.gov's structured results) and the JBI case-series checklist for the 4 cohort/case-series arms (Pirnay2024's three resistance-stratified arms rated Low risk — explicitly consecutive, complete, fully transparent per-patient reporting this review team verified directly; Onallah2023 rated Low-to-moderate risk, two Unclear items reflecting abstract-only access). Dispatched a fresh, full writer-critic review (not a delta-check) of intro/methods/results/discussion/abstract given two same-day rewrite waves — genuinely valuable: found 3 CRITICAL issues (PDR completely missing from Methods' own stated eligibility criteria and pre-specified stratification plan, despite being used as a full analyzed stratum throughout Results/Discussion/Abstract — traced to a genuine drafting omission since the strategy memo confirms PDR was always part of the pre-specified plan; Discussion's opening paragraph stated "12" pooled cells when Results/Abstract/the actual table all say 14 — a leftover from the second extraction wave that was propagated everywhere except Discussion's first paragraph; an arithmetic error, "60 of 87 patients," that didn't sum from its own stated components, actual answer 77) plus 2 MAJOR issues (revision-history "first run was X, then Y, now Z" narration bleeding into Results/Discussion prose — appropriate for this review's own internal logs, not for submission-ready manuscript text; a repetitive "X, not Y"/"rather than" antithesis construction appearing ~50 times across ~5,000 words) and several MINOR issues (abstract over 150 words; inconsistent naming for the same study across sections; GLMM acronym not parenthesized at first use; ROBINS-I never explicitly closed as "not applicable, here's why"). All CRITICAL and MINOR issues fixed; MAJOR #4 fully addressed, MAJOR #5 partially addressed (time-boxed partial trim, flagged to the critic for judgment on whether further trimming is required before the commit gate). Re-review dispatched to confirm the fix round actually cleared the 80/100 commit gate.
**Report:** `quality_reports/risk_of_bias_assessment_phage_therapy_mdr_pseudomonas.md` (new)

### 2026-07-22 — Writer-critic round 2 (76/100) + PDR propagation fix + round 3 dispatched
**Phase:** Execution → Peer-Review-adjacent (continuing the same writer-critic pair, round 2 of the "three strikes" protocol)
**Target:** `paper/main.tex` (title, abstract), `paper/sections/intro.tex`, `paper/sections/discussion.tex`
**Score:** 76/100 (round 2, up from 62/100 round 1) → fix applied → round 3 dispatched
**Verdict:** The same critic agent re-verified every claimed fix independently (recomputing arithmetic, re-grepping for the flagged patterns) rather than trusting the fix summary — confirmed CRITICAL #2 and #3 fully resolved, MAJOR #4 thoroughly resolved, all MINORs resolved, and the new RoB content well-integrated with no contradictions. But CRITICAL #1 (PDR) was only half-fixed: `methods.tex` itself was internally corrected, but the fix hadn't propagated to the Title, Abstract, Introduction (4 separate spots), or Discussion's Summary-opening and Conclusion-opening paragraphs — meaning the paper's own Title and Abstract still said "MDR/XDR" while its Results/Tables treated PDR as a fully analyzed fourth stratum, an even more referee-visible contradiction than the original internal-Methods one. Fixed all 5 locations; re-trimmed the abstract to hold exactly 150 words after adding "pandrug-resistant (PDR)"; deliberately left 3 mentions in `methods.tex` referring specifically to the discovery-phase comparative-design search unchanged (historically accurate as written — that search targeted "MDR/XDR" before PDR was incorporated, changing it would misrepresent what was actually searched at that stage). Dispatched the same critic agent for a third, final targeted check.
**Report:** `quality_reports/claim_source_map_phage_therapy_mdr_pseudomonas.md`

### 2026-07-22 — Writer-critic round 3 (79/100) + abstract regression fix + round 4 dispatched
**Phase:** Execution → Peer-Review-adjacent (round 3 of the same writer-critic pair)
**Target:** `paper/main.tex` (abstract)
**Score:** 79/100 (round 3, up from 76/100 round 2) → fix applied → round 4 dispatched
**Verdict:** The critic's round-3 check confirmed all 5 PDR-propagation fixes (Title, Abstract Background/Methods sentences, 4 Intro spots, both Discussion openings) and specifically praised the Discussion Conclusion fix for correctly updating the underlying logic ("neither XDR nor PDR can yet be pooled") rather than a mechanical word-swap. It also confirmed the 3 remaining bare "MDR/XDR" mentions in methods.tex were correctly left alone (genuinely historical, describing what was actually searched during the discovery-phase comparative-design premise). But it caught a **new regression I introduced myself** while trimming the abstract to hold 150 words after adding PDR: dropping "most" from "XDR, PDR, most routes, and monotherapy remained below threshold" turned an accurate hedge into a false absolute claim, since the paper's own Results/Table 2/Figure 2 report the multi-route "other" category *is* pooled (78.0% clinical success) — one of the paper's own headlined findings. This is exactly the kind of self-contradicting claim a real referee catches on a first read of the abstract. Fixed by restoring "most" and trimming one word elsewhere ("Conclusions: A resistance-stratified estimate is achievable for MDR" → "A resistance-stratified MDR estimate is achievable") to hold the 150-word cap. Dispatched a 4th, hopefully final, check.
**Report:** `quality_reports/claim_source_map_phage_therapy_mdr_pseudomonas.md`

### 2026-07-22 — Writer-critic round 4 (88/100, FINAL) — commit gate cleared
**Phase:** Execution → Peer-Review-adjacent (round 4, final round of the same writer-critic pair)
**Target:** `paper/main.tex` (abstract), full re-verification of all four sections
**Score:** 88/100 — PASSES the 80/100 commit gate
**Verdict:** The critic re-verified the abstract fix (word count exactly 150; "most routes" hedge restored and now consistent with Results/Table 2/Figure 2's route-"other" pooled finding) and then gave a full final accounting of the entire 4-round arc, independently re-checking every claim rather than accepting the running summary: all 3 CRITICAL issues (PDR scope, stale "12"→"14", "60"→"77" arithmetic) fully resolved and verified; MAJOR #4 (revision-history narration) fully removed; MAJOR #5 (repetitive "X, not Y" construction) explicitly flagged as intentionally left partial — cosmetic, not commit-blocking, but should be finished before a PR-gate (90) or submission-gate (95) pass; all MINORs resolved; new risk-of-bias content cross-checked line-by-line against `risk_of_bias_assessment...md` with zero inconsistencies found. This closes out this session's writer-critic cycle for `intro.tex`/`methods.tex`/`results.tex`/`discussion.tex`/abstract at commit quality (88/100).
**Report:** `quality_reports/claim_source_map_phage_therapy_mdr_pseudomonas.md`

---

**Outstanding for a future session, none blocking the commit gate:** (1) MAJOR #5 stylistic trim (repetitive antithesis construction), recommended before a 90-gate PR pass; (2) real author names/affiliations/contribution statement and a chosen target journal — placeholders remain, require the user's own decision; (3) EMBASE/Web of Science/Scopus searches — require the user's own institutional credentials, cannot be completed by this assistant; (4) PROSPERO registration — a real-world registry submission requiring the user's identity, cannot be completed by this assistant; (5) GRADE certainty ratings per outcome-stratum cell — unassigned, a precondition-complete but not-yet-executed step; (6) Liu et al. (2025) Tier-2 independent cross-validation spot-check — planned but not yet executed; (7) Onallah2023's exact AE count and Leitner2021's Pseudomonas-specific subgroup breakdown — both confirmed genuinely inaccessible short of full-text/author correspondence this review team does not have.

### 2026-07-22 (continued) — Post-commit-gate hardening: bibliography note-leak fix (critical) + claim-source-map resync
**Phase:** Execution (post-commit-gate polish, targeting PR gate)
**Target:** `paper/main.tex` (preamble), `paper/sections/{methods,results,discussion}.tex` (prose), `quality_reports/claim_source_map_phage_therapy_mdr_pseudomonas.md` (documentation)
**Score:** 88 → 87 → 73 → 70 (four consecutive full writer-critic reads, each surfacing a genuinely new, real, previously-undetected issue rather than repeating a prior one)
**Verdict:** After the 88/100 commit-gate pass, ran two rounds of stylistic trim targeting the disclosed MAJOR #5 ("X, not Y"/"rather than" repetition). The first scored 87/100 (density not meaningfully reduced, one twin-phrasing inconsistency between methods.tex/results.tex, one stacked-clause regression in results.tex). The second, broader pass fixing those plus more instances, triggered a fresh full read that found something unrelated and more serious: 36 of ~38 `Bibliography_base.bib` entries' internal `note` fields (verification provenance, reviewer names, internal file paths, a "scooping-risk" remark) were being printed directly into the compiled References section by biblatex's default `authoryear` behavior — invisible from `.tex`/`.bib` source, only visible by reading the compiled log/PDF, the same defect class as the earlier missing-author-field bug. Fixed via `\AtEveryBibitem{\clearfield{note}}` in `main.tex`'s preamble (suppresses printing without deleting the audit trail from the .bib source). Verified via `pdftotext` grep across the entire compiled PDF: zero leak markers remain. A subsequent full read (70/100) caught two more things: (a) my own self-verification claim ("Overfull hbox count dropped to 0") was inaccurate — 12 pre-existing, unrelated hbox warnings (all <110pt, none in the bibliography) remained and I had not re-checked after a later edit; corrected the claim in the claim-source map rather than leaving it standing; (b) the claim-source map's own per-section tables (written when each section was first drafted) had never been resynced after the Pirnay/Jault/Armata data-completion waves, so a verifier consulting them would validate against stale numbers (86.1%→77.2%, 66→87 patients, "only 5"→14 pooled cells, Egger's p=0.022/0.002 significant→p=0.48/0.49/0.07 not significant, etc.) even though the manuscript itself was already correct and this had been narrated (but not resynced) in later chronological entries of the same file. Resynced all affected rows with [SUPERSEDED]/[CURRENT] inline markers plus a reading note at the top of the file. Also finished varying the last "verified directly ... rather than an abstract" duplicate template (results.tex's RoB paragraph, echoing the one already fixed in methods.tex). Recompiled clean after every change (exit 0, zero fatal errors, zero undefined references throughout); final compile confirmed 12 pre-existing cosmetic hbox warnings (all pre-existing, all <110pt, unrelated to any fix made this session) and zero bibliography leak markers.
**Report:** `quality_reports/claim_source_map_phage_therapy_mdr_pseudomonas.md` ("Post-Commit-Gate Prose Polish + Bibliography note-Field Leak" and "Claim-Source Map Resync" entries)

---

**Decision point:** This is the 7th writer-critic round on this manuscript (62→76→79→88→87→73→70), each a genuinely new finding, not a repeat — consistent with `.claude/rules/agents.md`'s "different issue each round = incremental convergence, not a stuck loop" standard, but now past `workflow.md`'s soft 5-round-per-pipeline-loop guidance. Manuscript content itself (every number, every citation, every claim) has been independently re-verified as correct across all 7 rounds — the defects found in rounds 5-7 were entirely in auxiliary artifacts (prose repetition, a bibliography rendering bug, an internal QA document's staleness), not in the paper's substance. Pausing the autonomous critic-dispatch loop here to report status to the user rather than auto-dispatching an 8th round.

### 2026-07-23 — Writer-critic rounds 8-9 (68 → 81) + visual PDF verification made a standing step
**Phase:** Execution (post-commit-gate polish toward the 90 PR gate)
**Target:** `paper/figures/.../prisma_flow_diagram.tex`, `paper/tables/.../meta_threshold_relaxation_appendix.tex` (via `scripts/R/08_tables.R`), `paper/sections/results.tex`, claim-source map
**Score:** 68 (round 8) → 81 (round 9) — clears the 80 commit gate, below the 90 PR gate
**Verdict:** Round 8 (68/100) found two PDF-rendering-only-visible defects invisible to all 7 prior source-only rounds: the hand-built PRISMA figure showed stale arm counts (16/15 instead of 18/17), and Table 5's Flag column + notes were genuinely clipped off the page (110pt overfull). Both fixed at source (tikz edit; `08_tables.R` label shortening + pipeline re-run), visually confirmed via `pdftoppm` renders. Round 9 (81/100) confirmed those fixes and found a real off-by-one ("11 of 14" pooled cells diverge >5pp, actual is 12 of 14 per `transformation_divergence_flags.rds` — confirmed by running the R code), a stale claim-source-map row (5→4 relaxation cells), and Panel A/B captions without drawn panel labels (fixed via `subcaption`). Round 9 also flagged Table 2's 54pt overfull as needing visual check — rendered it directly and confirmed it does NOT clip (all 8 columns + notes fit within margins; cosmetic warning only). One new minor item (forest-plot study labels show raw dataset keys) deliberately deferred rather than risk pipeline surgery on the core pooling function at the finish line. Pattern across rounds 5-9: manuscript content verified correct every round; all defects were in auxiliary artifacts. Key process lesson now recorded: page-by-page visual PDF verification (not just source/log review) is required for this document type — three distinct defect classes in this project were invisible to source-only checks.
**Report:** `quality_reports/claim_source_map_phage_therapy_mdr_pseudomonas.md` ("Round 8 Findings..." and "Round 9 (81/100) Findings..." entries)

### 2026-07-23 — Native Scopus search integrated (corpus 13→22 studies) + 5 pipeline bug fixes
**Phase:** Discovery (search completion) → Execution (re-analysis + renumbering)
**Target:** whole pipeline + manuscript (abstract + 4 sections), PRISMA, Table 1, RoB, bibliography
**Score:** N/A (data integration + renumbering; writer dispatched for prose, derivative values manually reconciled)
**Verdict:** The user's native Scopus RIS (860 records) added 7 eligible studies the PubMed-only rounds missed and corrected the Law 2019 exclusion; corpus grew to 27 arms/22 studies/105 patients, 16 pooled cells. The expansion surfaced a genuine, honestly-reported new finding — Egger's mortality asymmetry is now significant (p=0.023) because two small fatal case reports cluster at the low-precision end — and diluted the MDR stratum's single-source dependence (Pirnay 79%→68%). Search reframed to 3 core databases per the user's directive. Five latent pipeline robustness bugs (NULL-primary POOLED cell, NA-condition phantom rows, fixed-effect accessor mismatch, forest prediction on fixed-effect, NA divergence message) were found and fixed. Compiled clean and visually verified (PRISMA 5-channel, Table 1 28 rows, Table 2 16 cells). Final main.pdf pending an Adobe Acrobat lock release.
**Report:** `quality_reports/claim_source_map_phage_therapy_mdr_pseudomonas.md` ("Native Scopus Database Search" entry)

### 2026-08-05 — Cribado por título (fase 2, pozo priorizado)
**Phase:** Discovery — selección de estudios (PRISMA 2020)
**Target:** `data/raw/screening_stage2_priorizado.csv` (13.509 registros)
**Score:** PASS — auditoría de control positivo 40/40 en los 92 lotes
**Verdict:** Pozo agotado. 460 avanzan a cribado por resumen; 13.049 excluidos con vocabulario cerrado (LAB 3.823 · ORG 3.014 · REV 2.668 · OFF 2.575 · VET 790 · SEC 74, más 79 motivos en texto libre de lotes iniciales). El contador del script muestra `pendientes: -14` porque el libro de decisiones conserva 14 filas huérfanas de la versión del corpus anterior a la deduplicación; los 13.509 registros actuales tienen decisión propia y ninguno quedó sin decidir.
**Report:** `data/raw/screening_stage2_pool_decisions.csv`

### 2026-08-05 — Saneamiento del índice de controles positivos
**Phase:** Discovery — selección de estudios (PRISMA 2020)
**Target:** `quality_reports/corpus_identifier_index.txt` y `scripts/check_identifier_traceability.R`
**Score:** PASS — auditoría de etapa 2 (40/40) y de etapa 3 (37/40 decididos) tras la corrección
**Verdict:** La auditoría de etapa 3 falló al excluir correctamente un metaanálisis: el índice atribuía a `Liu2025_perinephric` el DOI y el PMID de `Liu2025_ijaa`, un artículo distinto. El barrido encontró cuatro estudios contaminados por cosecha de identificadores de terceros (`Liu2025_perinephric`, `Li2025_biliary`, `Maddocks2019`, `Chan2025`). Se corrigieron las tres causas en el generador —fusión por stem autor+año, lectura de DOI dentro de `note`, y uso de la prosa de procedencia de la extracción— más un cuarto defecto preexistente: la clase de caracteres `[.,;:)\]]+$` nunca recortaba puntuación en base R (TRE), por lo que los DOI de PhagoBurn y Leitner llevaban años truncados en `10.1016/s1473-3099(18`. Retirados 10 identificadores ajenos, reparados 2 DOI truncados, añadido el PMID real de Liu2025_perinephric (41479406). Los 42 estudios siguen siendo trazables.
**Report:** `scripts/check_identifier_traceability.R` (mensajes de descarte por estudio)

### 2026-08-05 — Cribado por resumen (etapa 3, pozo priorizado)
**Phase:** Discovery — selección de estudios (PRISMA 2020)
**Target:** `data/raw/screening_stage3_pool_decisions.csv` (460 registros que avanzaron por título)
**Score:** PASS — los 40 estudios de control positivo conservan al menos un informe en texto completo
**Verdict:** Pozo agotado en las dos corrientes. Bases de datos: 389 decididos, 214 a texto completo, 175 excluidos (77 de ellos heredados del brazo por PMID, no rejuzgados). Registros de ensayos: 71 decididos sobre la ficha, 54 avanzan, 17 excluidos. Total 268 informes a texto completo. Recolector nuevo `scripts/screen_stage3_pool.py`, indexado por `record_id` porque 257 de los 460 no tienen PMID; corrientes separadas «bases de datos» y «registros» según PRISMA 2020, decidido por el usuario.
**Report:** `data/raw/screening_stage3_pool_decisions.csv`

### 2026-08-05 — Libro de cribado para revisión humana
**Phase:** Discovery — selección de estudios (PRISMA 2020)
**Target:** `quality_reports/cribado_pozo.xlsx` (generado por `scripts/export_cribado_pozo_xlsx.py`)
**Score:** N/A — artefacto de revisión, no puntuado
**Verdict:** Ocho hojas con TODAS las decisiones del pozo (13.509 en etapa 2, 389 + 71 en etapa 3), no solo las supervivientes. La hoja `Texto_completo` es la lista de trabajo: 268 informes agrupados en 233 estudios distintos, con columnas vacías para el revisor y dos particiones útiles: (a) 46 informes que ya pertenecen a uno de los 42 estudios extraídos frente a 222 candidatos nuevos; (b) estado de recuperación, que expone 70 registros cuyo único DOI es el sustituto de Cochrane CENTRAL y 10 sin identificador alguno. Comprobación adicional al control positivo: los 42 estudios del corpus extraído conservan al menos un informe entre los 268 — ninguno se perdió en el cribado.
**Report:** `quality_reports/cribado_pozo.xlsx`

### 2026-08-05 — Resolución del cuello de botella de recuperación (etapa 4)
**Phase:** Discovery → recuperación de textos completos
**Target:** `scripts/resolve_fulltext_ids.py`, `data/raw/fulltext_identifiers.csv`, hoja `Recuperacion` de `cribado_pozo.xlsx`
**Score:** N/A
**Verdict:** El "80 de 268 irrecuperables" que se informó antes era erróneo por partida doble. Primero, `estado_id()` comprobaba el DOI antes que el PMID y, como Cochrane CENTRAL asigna un DOI sustituto (`10.1002/central/...`) a todo lo que indexa, marcaba como irrecuperables 35 informes que tenían PMID o NCT: los sin vía real eran 45. Segundo, de esos 45, **21 llevaban su identificador dentro del propio registro** — 17 en la URL de `trialsearch.who.int` del campo `journal` (ChiCTR, CTIS, IRCT, ACTRN, KCT, CTRI) y 4 como código de protocolo en el título (PHRC-N/2015/AS-01, Phage4Cure-001, BMX-04-002). Quedan **24 que exigen búsqueda por cita**: 15 resúmenes de congreso indexados solo en CENTRAL y 7 artículos sin DOI en el registro. Se comprobó contra PubMed que varios de esos resúmenes de congreso no están indexados allí, así que la vía es la cita (revista+año), no el PMID. Además se detectaron 10 duplicados internos probables (solapamiento de título ≥0,80 con un informe ya identificado), entre ellos tres registros del mismo ensayo CYPHY.
**Report:** `data/raw/fulltext_identifiers.csv`

### 2026-08-05 — Cierre de la recuperación: 45 de 45 resueltos
**Phase:** Discovery → recuperación de textos completos
**Target:** `data/raw/fulltext_identifiers.csv`, `scripts/resolve_fulltext_ids.py`
**Score:** N/A — comprobación de coherencia del canal completa: 5/5 OK
**Verdict:** Los 268 informes tienen vía de recuperación; ninguno queda sin resolver. 38 con identificador recuperado (17 del ICTRP leídos del campo `journal`, 4 códigos de protocolo CTIS/EudraCT del título, 17 atribuidos a su ensayo padre) y 7 con cita verificada. Las atribuciones a ensayo padre están codificadas a mano en `ATRIBUCION` con su justificación línea a línea: los siete resúmenes de BX004-A se apoyan en que el propio resumen nombra el producto, no en el parecido del título — el emparejamiento difuso apuntaba erróneamente a NCT05453578 (WRAIR-PAM-CF1), que es otro ensayo. Se comprobó contra PubMed que los 7 restantes (Int J Diabetes Dev Ctries, Pharmaceutisch Weekblad, Eur Urol Suppl, Jpn J Clin Ophthalmol, Surgical Chronicles, Nephrol Dial Transplant, Rev Cubana Angiol) NO están indexados: no tienen PMID que buscar, se recuperan por cita.
**Report:** `quality_reports/cribado_pozo.xlsx` (hoja Recuperacion)

### 2026-08-05 — Enmienda de protocolo: unidad de inclusión y resúmenes de congreso
**Phase:** Selección de estudios → preparación de la extracción
**Target:** `scripts/group_reports_into_studies.py`, `data/raw/study_groups.csv`, memo de estrategia §5, `quality_reports/decisions/2026-08-05_unidad-de-inclusion-y-resumenes-de-congreso.md`
**Score:** N/A — comprobación de invariantes de la agrupación: 5/5 OK
**Verdict:** Decidido con el usuario que los resúmenes de congreso son elegibles y que la unidad de inclusión es el estudio, no el informe. Los 268 informes se agrupan en **219 estudios**: 156 extraíbles, 60 solo-registro (en curso o sin resultados; fuera de la síntesis, listados aparte) y 3 solo-resumen (posiciones 288, 888, 4039), que se incluyen y entran en la nueva comprobación de sensibilidad #14. La agrupación destapó dos errores que habrían llegado a la extracción: (1) los siete resúmenes del BX004-A figuraban como siete estudios distintos, con riesgo de meter los mismos pacientes varias veces en el metaanálisis — ahora son once informes de un solo estudio; (2) el artículo del BX004-A en Nature Communications (PMID 40593506) no lleva el NCT en su registro, así que el ensayo salía clasificado como «solo-resumen» teniendo publicación completa y se habría ido al análisis de sensibilidad que excluye justo esos. Se corrigió rastreando el NCT dentro del resumen, aceptándolo solo si ya existe como registro propio de otro informe del pozo.
**Report:** `quality_reports/decisions/2026-08-05_unidad-de-inclusion-y-resumenes-de-congreso.md`

### 2026-08-05 — Maquinaria de doble extracción
**Phase:** Extracción de datos
**Target:** `scripts/extraction_schema.py`, `scripts/make_extraction_forms.py`, `scripts/compare_extractions.py`
**Score:** N/A — probada de punta a punta: 10 discrepancias sembradas, 10 detectadas, 0 falsos positivos
**Verdict:** Formularios ciegos para 159 estudios y comparador que calcula kappa de Cohen por variable, acuerdo exacto y diferencia media en numéricas, más lista de conflictos con columnas de resolución. Cuatro decisiones de medida quedaron documentadas porque ninguna es neutral: (1) la concordancia se mide sobre el valor normalizado, ya que `route` tiene 23 variantes que son casi todas `other (...)` con distinto paréntesis y comparadas literalmente hundirían la kappa por artefacto de redacción; (2) las filas presentes en una sola extracción se cuentan como desacuerdo de cobertura, no de valor; (3) la kappa sin variación se informa como "no calculable" en vez de 0 o NaN; (4) el emparejamiento va por `id_provisional` y no por `study_id`, porque el pozo no guarda el autor y dos revisores escribirían el id de forma distinta — en la prueba escribieron ids completamente distintos y aun así se emparejaron las 159 filas.
**Report:** `quality_reports/decisions/2026-08-05_unidad-de-inclusion-y-resumenes-de-congreso.md` (adenda)

### 2026-08-10 19:50 — Pre-extracción desde resumen (microbiología + metodología)
**Phase:** Execution
**Target:** data/extraction/pre_extraccion_desde_resumen.csv
**Score:** N/A (insumo de contraste, no extracción definitiva)
**Verdict:** 159 de 159 estudios extraíbles pre-extraídos desde el resumen, cada uno con alerta de microbiología y alerta de metodología. Todos marcados PARTIAL: no sustituyen la lectura del texto completo de Danny y Nataly.
**Report:** data/extraction/pre_extraccion_desde_resumen.csv

### 2026-08-10 20:05 — Comprobación de coherencia del canal completo
**Phase:** Execution
**Target:** corpus → etapa 1 → pozo → etapa 2 → etapa 3 → estudios → pre-extracción
**Score:** 15 comprobaciones OK, 0 fallos
**Verdict:** La cadena cuadra eslabón por eslabón. La comprobación destapó que BVS (638 registros) estaba en disco pero fuera del manifiesto y nunca se había cribado.
**Report:** quality_reports/decisions/2026-08-10_incorporacion-bvs-al-corpus.md

### 2026-08-10 20:20 — Incorporación de BVS y reconstrucción del corpus
**Phase:** Discovery / Cribado
**Target:** data/raw/sources.json, screening_corpus_all.csv, screening_stage2_pool_decisions.csv
**Score:** auditoría de control positivo PASS (40/40 estudios conservan informe)
**Verdict:** Corpus 16 698 → 17 129 informes; pozo 13 509 → 13 894; 394 títulos nuevos cribados y todos excluidos (LAB 230, REV 56, OFF 54, VET 44, ORG 8, SEC 2). Aporte neto a la síntesis: cero, pero ahora demostrado en vez de supuesto. Corregido además un defecto del lector: el marcado HTML de los títulos de BVS impedía la deduplicación por título y contaminaba el corpus.
**Report:** quality_reports/decisions/2026-08-10_incorporacion-bvs-al-corpus.md

### 2026-08-10 21:10 — Separación revisión / metaanálisis y corrección de índices posicionales
**Phase:** Execution
**Target:** revision_sistematica/, metaanalisis/, scripts/
**Score:** 24 comprobaciones OK, 0 fallos; canal idempotente
**Verdict:** Datos separados en dos árboles sin ficheros compartidos. La migración destapó tres tablas curadas a mano indexadas por posición en el pozo: partían el BX004-A y el TP-102, y corrían la numeración EST-NNN doce puestos, que es la clave de los cuadernos de Danny y Nataly. Las tres reindexadas a record_id; numeración EST ahora estable entre ejecuciones.
**Report:** quality_reports/decisions/2026-08-10_incorporacion-bvs-al-corpus.md
